Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Original Versus Generic Lenalidomide in Patients with Relapsed Multipl Myeloma: Comprasion of Effectivity and Adverse Events

Zahit Bolaman, Sehmus Ertop, Atakan Turgutkaya, Selim Cem, Ayse Hilal Eroglu Kucukerdiler, Birsen Sahip, Irfan Yavasoglu, MD

Blood (2019) 134 (Supplement_1): 5594.

https://doi.org/10.1182/blood-2019-131093

Published: 2019

Journal Articles

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Jennifer L. Crombie, MD, Svitlana Tyekucheva, PhD, Alexandra Savell, BS, Karen Francoeur, RN, Mark Choiniere, BA, Josie Montegaard, NP, Jacob D. Soumerai, MD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD, Matthew S. Davids, MD

Blood (2019) 134 (Supplement_1): 1763.

https://doi.org/10.1182/blood-2019-127343

Published: 2019

Journal Articles

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 3165.

https://doi.org/10.1182/blood-2019-124370

Published: 2019

Journal Articles

Simulated Treatment Comparison (STC) of Human Mesenchymal Stromal Cells (Remestemcel-L, REM) and Ruxolitinib (RUX) for Steroid-Refractory Acute Graft-Versus-Host Disease (SR aGVHD) Pediatric Patients

Tracy Westley, MPH, Dimitrios Tomaras, MSc, Eric Strati, PharmD, Donna Skerrett, MD MS, Anna Forsythe, PharmD, MBA, MMSc, Gabriel Tremblay, DBA, MSc, BS

Blood (2019) 134 (Supplement_1): 4545.

https://doi.org/10.1182/blood-2019-131098

Published: 2019

Journal Articles

Experience of Generic Imatinib As a First Line Therapy for Patients with Chronic Myeloid Leukemia in a Single Reference Institution

Gabriel Carvalho Pereira, MD, Fernanda B da Silva, BSc and MSc, Luisa Espirito Santo Oliveira, Pedro Marques Garibaldi, MD, Lorena Lobo Figueiredo-Pontes, MD PhD, Belinda Pinto Simões, MD PhD, Leonardo Carvalho Palma, MD PhD, Fabiola Traina, MD PhD

Blood (2019) 134 (Supplement_1): 5916.

https://doi.org/10.1182/blood-2019-132045

Published: 2019

Journal Articles

Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study

John F. Tisdale, MD, Julie Kanter, MD, Markus Y. Mapara, MD PhD, Janet L. Kwiatkowski, MD, Lakshmanan Krishnamurti, MD, Manfred Schmidt, PhD, Alexandra L. Miller, Francis J. Pierciey, Jr., Weiliang Shi, PhD, Jean-Antoine Ribeil, MD PhD, Mohammed Asmal, MD PhD, Alexis A. Thompson, MD MPH, Mark C. Walters, MD

Blood (2018) 132 (Supplement 1): 1026.

https://doi.org/10.1182/blood-2018-99-113480

Published: 2018

Journal Articles

Cyclosporin Dosing and Toxicity Following Allogeneic Haematopoietic Stem Cell Transplant at Austin Health

Danielle H Robinson, Charlotte Hughes, BBiomedSci, MD, Simon Zhao-Xiong He, MBBS, FRACP, FRCPA, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD

Blood (2018) 132 (Supplement 1): 5701.

https://doi.org/10.1182/blood-2018-99-116146

Published: 2018

Journal Articles

Posterior Reversible Encephalopathy Syndrome in Pediatric Oncology and Post Bone Marrow Transplant: Single Center Experience and Systematic Review

Hwazen A Shash, MD, Saad Aldaama, MD, Ghufran A Al-Hawaj, MSN, Abdullah M Alfareed, MD, Sameera A Alafghani, MD

Blood (2018) 132 (Supplement 1): 5694.

https://doi.org/10.1182/blood-2018-99-115808

Published: 2018

Journal Articles

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Blood (2018) 132 (Supplement 1): 561.

https://doi.org/10.1182/blood-2018-99-110595

Published: 2018

Journal Articles

Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy

Blood (2017) 130 (Supplement 1): 1841.

https://doi.org/10.1182/blood.V130.Suppl_1.1841.1841

Published: 2017

Journal Articles

Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)

William G Wierda, MD PhD, Matthew S. Davids, MD, Richard R. Furman, Bruce D. Cheson, MD, Paul M. Barr, MD, Herbert Eradat, Leonard Heffner, MD, Jeffrey Jones, MD, Lang Zhou, Maria Verdugo, MD, Rod A. Humerickhouse, Jalaja Potluri, Michael Choi, MD

Blood (2017) 130 (Supplement 1): 3025.

https://doi.org/10.1182/blood.V130.Suppl_1.3025.3025

Published: 2017

Journal Articles

Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy

Sangmin Lee, MD, Pinkal Desai, MDMPH, Bianca Edirisinghe, Samantha Pianello, Jack W. Singer, MD, Michael Samuel, MD, Ellen K Ritchie, MD, Gail J. Roboz, MD

Blood (2017) 130 (Supplement 1): 2966.

https://doi.org/10.1182/blood.V130.Suppl_1.2966.2966

Published: 2017

Journal Articles

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy

Sudipto Mukherjee, MD, PhD, M.P.H., Paul Elson, PhD, Samjhana Bogati, BSN, Ashley Woltman, BSN, RN, John Desamito, Aaron T. Gerds, MD MS, Hetty E. Carraway, MD MBA, Anjali S. Advani, Yogen Saunthararajah, MD, Jaroslaw P Maciejewski, MD PhD FACP, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS

Blood (2016) 128 (22): 447.

https://doi.org/10.1182/blood.V128.22.447.447

Published: 2016

Journal Articles

The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Bei Hu, MD, Anas Younes, MD, Linda Claret, Lei Feng, MS, Jason R. Westin, MD, Nathan Fowler, MD, Sattva Neelapu, MD, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Felipe Samaniego, MD, Luis E. Fayad, MD, Loretta J. Nastoupil, MD, Amanda R Copeland, RN, MSN, CNS, Michelle A Fanale, MD, Yasuhiro Oki, MD

Blood (2016) 128 (22): 1833.

https://doi.org/10.1182/blood.V128.22.1833.1833

Published: 2016

Journal Articles

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Ramon Garcia-Sanz, MD PhD, Anna Sureda, MD PhD, Ana Pilar Gonzalez, MD, Fatima De la Cruz, MD PhD, Blanca Sanchez-Gonzalez, MD PhD, Antonia Rodriguez, MD PhD, Eva Domingo-Domenech, MD, Moreno Miriam, MD, Moreno Miriam, MD, Javier Lopez, Sr., MD PhD, Piñana Luis Jose, Gabriela Rodríguez, MD PhD, Miguel Canales, MD PhD, Antonio Gutierrez, MD PhD, Maria Dolores Caballero, MD PhD, Carmen Martinez, MD PhD

Blood (2016) 128 (22): 1109.

https://doi.org/10.1182/blood.V128.22.1109.1109

Published: 2016

Journal Articles

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

Rajat Bannerji, MD PhD, Jennifer R. Brown, MD PhD, Ranjana H Advani, MD, Jon Arnason, MD, Susan M. O'Brien, MD, John N. Allan, MD, Julio C. Chavez, MD, Jeffrey A. Barnes, MD PhD, Robin Joyce, MD, Stephen Ansell, MD PhD, Max S Topp, MD, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Ana Kostic, PhD, Anne Paccaly, PharmD, PhD, Bo Gao, PhD, Pamela A. Trail, PhD, Israel Lowy, MD PhD, Carrie Brownstein, MD

Blood (2016) 128 (22): 621.

https://doi.org/10.1182/blood.V128.22.621.621

Published: 2016

Journal Articles

Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results

Courtney D DiNardo, MD, Joseph Rosenthal, MD MS, Michael Andreeff, MD PhD, Oleg Zernovak, MD, Prasanna Kumar, PhD, Roohi Gajee, PhD, Shuquan Chen, PhD, Michael Rosen, PhD, Saeheum Song, PhD, Jarema Kochan, PhD, Tharin Limsakun, PhD, Rebecca Olin, MD

Blood (2016) 128 (22): 593.

https://doi.org/10.1182/blood.V128.22.593.593

Published: 2016

Journal Articles

A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

Eytan M. Stein, MD, Guillermo Garcia-Manero, MD, David A. Rizzieri, MD, Raoul Tibes, MD PhD, Jesus G. Berdeja, MD, Mojca Jongen-Lavrencic, MD PhD, Jessica K. Altman, MD, Hartmut Dohner, MD, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Greg Fine, MS, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Richard Koche, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Bob Lowenberg, MD PhD, Martin S Tallman, MD

Blood (2015) 126 (23): 2547.

https://doi.org/10.1182/blood.V126.23.2547.2547

Published: 2015

Journal Articles

The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia

Blood (2014) 124 (21): 387.

https://doi.org/10.1182/blood.V124.21.387.387

Published: 2014

Journal Articles

Relationship of Epidermal Growth Factor to Cyclosporine-Assocated Magnesium Wasting and Clinical Outcomes Post-Allogeneic Hematopoietic Cell Transplantation

Fiona C. He, MD, Michael R. Verneris, MD, Sarah A. Cooley, MD MS, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Angela Panoskaltsis-Mortari, PhD, Daniel J. Weisdorf, MD, Shernan G. Holtan, MD

Blood (2014) 124 (21): 3914.

https://doi.org/10.1182/blood.V124.21.3914.3914

Published: 2014

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Original Versus Generic Lenalidomide in Patients with Relapsed Multipl Myeloma: Comprasion of Effectivity and Adverse Events

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma

Simulated Treatment Comparison (STC) of Human Mesenchymal Stromal Cells (Remestemcel-L, REM) and Ruxolitinib (RUX) for Steroid-Refractory Acute Graft-Versus-Host Disease (SR aGVHD) Pediatric Patients

Experience of Generic Imatinib As a First Line Therapy for Patients with Chronic Myeloid Leukemia in a Single Reference Institution

Current Results of Lentiglobin Gene Therapy in Patients with Severe Sickle Cell Disease Treated Under a Refined Protocol in the Phase 1 Hgb-206 Study

Cyclosporin Dosing and Toxicity Following Allogeneic Haematopoietic Stem Cell Transplant at Austin Health

Posterior Reversible Encephalopathy Syndrome in Pediatric Oncology and Post Bone Marrow Transplant: Single Center Experience and Systematic Review

Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study

Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy

Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi)

Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy

A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Older Patients with Acute Myeloid Leukemia Undergoing Remission Induction Therapy

The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients (pts) with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow Transplantation (GELTAMO)

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

Phase 1 Dose Escalation Study of MDM2 Inhibitor DS-3032b in Patients with Hematological Malignancies - Preliminary Results

A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition

The DOT1L Inhibitor EPZ-5676: Safety and Activity in Relapsed/Refractory Patients with MLL-Rearranged Leukemia

Relationship of Epidermal Growth Factor to Cyclosporine-Assocated Magnesium Wasting and Clinical Outcomes Post-Allogeneic Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only